Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

Abstract Background Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-speci...

Full description

Bibliographic Details
Main Authors: Yvonne W. S. Jauw, Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, Florian Heil, Adriaan A. Lammertsma, Henk M. W. Verheul, Otto S. Hoekstra, Guus A. M. S. van Dongen, C. Willemien Menke-van der Houven van Oordt
Format: Article
Language:English
Published: SpringerOpen 2018-01-01
Series:EJNMMI Research
Subjects:
PET
Antibody
Anti-CD44 humanized antibody
RG7356
Molecular imaging
Online Access:http://link.springer.com/article/10.1186/s13550-018-0358-8

Internet

http://link.springer.com/article/10.1186/s13550-018-0358-8

Similar Items